Open in Screener

MPLT

MapLight Therapeutics Inc

Feb 20 • 04:00PM ET

17.88

-0.04 -0.22 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO SCHA IWN IWO IWC SCHB VTWG

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	66.74%	Shs Outstand	45.37M	Perf Week	3.83%
Market Cap	811.27M	Forward P/E	-	EPS next Y	-	Insider Trans	26.65%	Shs Float	15.09M	Perf Month	5.49%
Enterprise Value	1.10B	PEG	-	EPS next Q	-0.99	Inst Own	26.22%	Short Float	8.42%	Perf Quarter	20.24%
Income	-	P/S	-	EPS this Y	-	Inst Trans	49.00%	Short Ratio	4.70	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.27M	Perf YTD	1.79%
Book/sh	-6.04	P/C	3.57	EPS next 5Y	-	ROE	-	52W High	21.55 -17.03%	Perf Year	-
Cash/sh	5.01	P/FCF	-	EPS past 3/5Y	-60.77% -	ROIC	-	52W Low	12.24 46.08%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.78% 7.49%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.22	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.22	EPS Q/Q	-41.88%	SMA20	1.36%	Beta	-	Target Price	31.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-1.39%	Rel Volume	0.43	Prev Close	17.92
Employees	-	LT Debt/Eq	0.02	Earnings	Dec 04 BMO	SMA200	4.47%	Avg Volume	270.26K	Price	17.88
IPO	Oct 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-2055.36% -	Trades		Volume	115,651	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-25	Initiated	Stifel	Buy	$28
Nov-21-25	Initiated	Morgan Stanley	Overweight	$34
Nov-21-25	Initiated	Leerink Partners	Outperform	$30
Nov-21-25	Initiated	Jefferies	Buy	$32

Jan-09-26 07:00AM	MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 (GlobeNewswire)
Jan-05-26 07:00AM	MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis (GlobeNewswire)
Dec-16-25 07:00AM	SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies (GlobeNewswire)
Dec-04-25 07:00AM	MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress (GlobeNewswire) +8.39%
Nov-07-25 07:26PM	MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors (Barrons.com)
09:06AM	Loading…
Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pavlov George	Director	Feb 18 '26	Buy	17.48	10,658	186,302	10,658	Feb 20 06:25 PM
Pavlov George	Director	Feb 20 '26	Buy	17.86	9,920	177,171	25,000	Feb 20 06:25 PM
Pavlov George	Director	Feb 19 '26	Buy	17.57	4,422	77,695	15,080	Feb 20 06:25 PM
ROBERT MALENKA	Director	Feb 20 '26	Proposed Sale	18.03	2,195	39,577		Feb 20 04:16 PM
Malenka Robert C.	Director	Feb 13 '26	Sale	18.21	12,116	220,632	339,254	Feb 18 07:33 PM
ROBERT MALENKA	Director	Feb 13 '26	Proposed Sale	18.21	12,116	220,686		Feb 13 04:08 PM
Garnett Timothy John	Director	Feb 10 '26	Buy	17.89	14,124	252,678	14,124	Feb 12 05:45 PM
Malenka Robert C.	Director	Feb 10 '26	Sale	18.12	6,622	119,991	351,611	Feb 12 05:45 PM
Malenka Robert C.	Director	Feb 11 '26	Sale	18.00	241	4,338	351,370	Feb 12 05:45 PM
ROBERT MALENKA	Director	Feb 11 '26	Proposed Sale	18.00	241	4,338		Feb 11 04:13 PM
ROBERT MALENKA	Director	Feb 10 '26	Proposed Sale	18.12	6,622	119,963		Feb 10 04:22 PM
Malenka Robert C.	Director	Feb 02 '26	Sale	18.02	7,039	126,843	358,234	Feb 04 09:15 PM
Malenka Robert C.	Director	Feb 03 '26	Sale	18.00	1	18	358,233	Feb 04 09:15 PM
ROBERT MALENKA	Director	Feb 03 '26	Proposed Sale	18.00	1	18		Feb 03 04:15 PM
ROBERT MALENKA	Director	Feb 02 '26	Proposed Sale	18.02	7,039	126,835		Feb 02 04:37 PM
Malenka Robert C.	Director	Jan 29 '26	Sale	18.55	21,262	394,410	371,885	Jan 30 08:50 PM
Malenka Robert C.	Director	Jan 28 '26	Sale	18.65	6,524	121,704	393,147	Jan 30 08:50 PM
Malenka Robert C.	Director	Jan 30 '26	Sale	18.11	6,612	119,743	365,273	Jan 30 08:50 PM
ROBERT MALENKA	Director	Jan 30 '26	Proposed Sale	18.11	6,612	119,737		Jan 30 04:17 PM
ROBERT MALENKA	Director	Jan 29 '26	Proposed Sale	18.55	21,262	394,470		Jan 29 04:06 PM
ROBERT MALENKA	Director	Jan 28 '26	Proposed Sale	18.65	6,524	121,690		Jan 28 04:20 PM
Novo Holdings A/S	10% Owner	Oct 28 '25	Buy	17.00	952,941	16,199,997	3,686,622	Oct 30 04:31 PM
Catalyst4, Inc.	10% Owner	Oct 28 '25	Buy	17.00	5,441,176	92,499,992	19,697,464	Oct 29 04:16 PM

Open in Screener

IOBT

IO Biotech Inc

Feb 20 • 04:00PM ET

0.3400

-0.0205 -5.69 %

Healthcare • Biotechnology • Denmark • NASD

Peers: ARGX FATE TVRD APLS AFMD KURA ANAB ALLK ALXO CTMX

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	16.12%	Shs Outstand	69.69M	Perf Week	-4.36%
Market Cap	24.46M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	0.00%	Shs Float	60.35M	Perf Month	63.78%
Enterprise Value	11.92M	PEG	-	EPS next Q	-0.21	Inst Own	40.11%	Short Float	8.93%	Perf Quarter	-58.79%
Income	-88.35M	P/S	-	EPS this Y	30.11%	Inst Trans	-10.13%	Short Ratio	0.55	Perf Half Y	-81.91%
Sales	0.00M	P/B	26.01	EPS next Y	71.38%	ROA	-136.03%	Short Interest	5.39M	Perf YTD	-44.16%
Book/sh	0.01	P/C	0.80	EPS next 5Y	39.99%	ROE	-240.48%	52W High	2.79 -87.81%	Perf Year	-69.37%
Cash/sh	0.43	P/FCF	-	EPS past 3/5Y	17.72% -25.33%	ROIC	-484.32%	52W Low	0.21 65.61%	Perf 3Y	-87.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.08% 20.08%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	2.36%	Oper. Margin	-	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.70	Recom	3.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.01	EPS Q/Q	65.65%	SMA20	1.71%	Beta	0.42	Target Price	0.43
Payout	-	Debt/Eq	19.91	Sales Q/Q	-	SMA50	-33.39%	Rel Volume	0.05	Prev Close	0.36
Employees	80	LT Debt/Eq	19.04	Earnings	Nov 14 BMO	SMA200	-69.15%	Avg Volume	9.82M	Price	0.34
IPO	Nov 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	59.88% -	Trades		Volume	511,025	Change	-5.69%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-26	Downgrade	Piper Sandler	Overweight → Neutral	$0.50
Jan-08-26	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$0.36
Sep-30-25	Downgrade	TD Cowen	Buy → Hold
Sep-30-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$0.39

Feb-13-26 09:55AM	Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing (Zacks)
Jan-30-26 08:05AM	IO Biotech Provides Corporate Update (GlobeNewswire) -8.28%
Jan-27-26 08:00AM	Piper downgrades IO Biotech amid strategic alternatives evaluation (TipRanks) +6.16%
Jan-21-26 05:38AM	Moderna cancer vaccine holds up; IO Biotech considers a sale (BioPharma Dive) -59.74%
05:30AM	IO Biotech Announces Exploration of Strategic Alternatives (GlobeNewswire)
04:05PM	Loading…
Dec-15-25 04:05PM	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications (GlobeNewswire) -12.54%
Nov-26-25 10:46AM	IO Biotech Announces Participation in Upcoming December Investor Conferences (GlobeNewswire)
Nov-19-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why (Zacks) -8.90%
Nov-14-25 08:05AM	IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-12-25 08:30AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -6.00%
Nov-07-25 09:00AM	IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +6.96%
Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire) -9.11%
Oct-20-25 02:30AM	IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 (GlobeNewswire) +25.18%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) +6.83%
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
07:05AM	Loading…
Sep-29-25 07:05AM	IO Biotech Provides Update Following Pre-BLA Meeting with FDA (GlobeNewswire) -76.89%
Sep-23-25 08:05AM	IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 (GlobeNewswire) +7.38%
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire) -11.54%
Sep-04-25 08:05AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-03-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-26-25 08:39AM	H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14 (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-14-25 04:05PM	IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) +68.75%
12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-11-25 01:23PM	IO Biotech to pursue cancer vaccine approval despite Phase III miss (Clinical Trials Arena) -41.99%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:02AM	IO Biotech sees path forward for skin cancer vaccine despite study setback (BioPharma Dive)
08:00AM	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio plus KEYTRUDA (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed (GlobeNewswire)
Aug-10-25 08:00AM	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire)
May-28-25 09:55AM	IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:05AM	Loading…
May-20-25 08:05AM	IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 12:11PM	IO Biotech price target raised to $14 from $12 at H.C. Wainwright (TipRanks)
May-14-25 08:05AM	IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-26-25 03:05PM	IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM	IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 (GlobeNewswire)
Mar-25-25 04:35PM	IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.00%
Mar-18-25 08:00AM	IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 (GlobeNewswire)
Mar-04-25 04:17PM	IO Biotech Reports 2024 Business Highlights (GlobeNewswire) +5.91%
Feb-23-25 12:07PM	IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference (GlobeNewswire)
Feb-20-25 08:05AM	IO Biotech to Present at the 45th Annual Cowen Health Care Conference (GlobeNewswire) +11.00%
Feb-04-25 08:05AM	IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate (GlobeNewswire) +6.74%
Jan-10-25 11:10AM	IO Biotech enrols all subjects in Phase II trial of cancer combination therapy (Clinical Trials Arena)
Jan-09-25 08:05AM	IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer (GlobeNewswire)
Dec-20-24 08:05AM	IO Biotech secures up to 57.5 million in debt financing from the European Investment Bank (GlobeNewswire)
Nov-12-24 07:05AM	IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -11.68%
Nov-11-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 10:00AM	IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study (GlobeNewswire) +6.03%
Oct-04-24 09:00AM	IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +13.86%
Sep-14-24 02:30AM	IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (GlobeNewswire)
Sep-02-24 06:53AM	IO Biotechs melanoma treatment trial to continue after IDMC review (Clinical Trials Arena)
Aug-30-24 04:05PM	IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire) -33.33%
Aug-26-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:05AM	IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +17.69%
Jul-25-24 04:05PM	IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
May-23-24 08:30AM	IO Biotech to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:54PM	IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024 (InvestorPlace)
07:55AM	IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-24-24 04:30PM	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 08:30AM	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (GlobeNewswire)
Apr-09-24 12:00PM	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (GlobeNewswire)
Apr-05-24 08:30AM	IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
08:30AM	IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
Mar-07-24 02:01PM	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com) +6.63%
Mar-06-24 04:11PM	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-24 10:52PM	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 (InvestorPlace)
04:40PM	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-26-24 04:05PM	IO Biotech to Present at 44th Annual Cowen Health Care Conference (GlobeNewswire)
Dec-21-23 08:30AM	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial (GlobeNewswire)
Nov-13-23 08:12AM	IO Biotech Announces 2023 Third Quarter Results (GlobeNewswire)
08:00AM	IO Biotech Appoints Helen Collins, MD, to its Board of Directors (GlobeNewswire)
Nov-10-23 08:00AM	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma (GlobeNewswire)
Nov-08-23 04:30PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-23 08:30AM	IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +8.38%
Oct-23-23 01:00AM	Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) -5.05%
Oct-03-23 04:30PM	IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +10.22%
Sep-12-23 08:05AM	IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (GlobeNewswire) -13.20%
Sep-06-23 08:35AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:59AM	10 Best New Penny Stocks to Buy Now (Insider Monkey)
Aug-16-23 09:01PM	Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc (GuruFocus.com)
Aug-11-23 08:30AM	IO Biotech Announces 2023 Second Quarter Results (GlobeNewswire)
08:05AM	IO Biotech Appoints Heidi Hunter to its Board of Directors (GlobeNewswire)
Aug-08-23 08:05AM	IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Aug-07-23 08:30AM	IO Biotech, Inc. Announces $75 Million Private Placement Financing (GlobeNewswire)
Jul-28-23 08:05AM	IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center (GlobeNewswire)
Jul-25-23 04:05PM	IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-18-23 04:05PM	IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +27.33%
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:42PM	Why Are IO Biotech Shares Trading Lower Today (Benzinga) -26.48%
08:00AM	IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (GlobeNewswire)
Jun-01-23 08:30AM	IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (GlobeNewswire)
May-30-23 04:35PM	IO Biotech to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	IO Biotech Announces 2023 First-Quarter Results (GlobeNewswire) +9.69% -7.91%
May-02-23 07:22AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-23 06:14AM	The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 04:11PM	IO Biotech Announces 2022 Fourth-Quarter and Year-End Results (GlobeNewswire) -7.79%
Feb-22-23 07:00AM	IO Biotech to Participate in March 2023 Investor Conferences (GlobeNewswire)
Jan-23-23 08:00AM	IO Biotech Announces Appointment of Devin Smith as General Counsel (GlobeNewswire)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hunter Heidi	Director	May 30 '25	Buy	1.39	15,000	20,884	15,000	Jun 02 07:53 AM

Open in Screener

SPRB

Spruce Biosciences Inc

Feb 20 • 04:00PM ET

49.72

-2.90 -5.51 %

Healthcare • Biotechnology • USA • NASD

SPRB Spruce Biosciences Inc daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-84.76	Insider Own	16.88%	Shs Outstand	1.07M	Perf Week	-40.07%
Market Cap	53.22M	Forward P/E	-	EPS next Y	-32.34	Insider Trans	-0.00%	Shs Float	0.89M	Perf Month	-37.00%
Enterprise Value	43.90M	PEG	-	EPS next Q	-9.16	Inst Own	67.14%	Short Float	8.06%	Perf Quarter	-56.77%
Income	-47.88M	P/S	76.03	EPS this Y	78.05%	Inst Trans	66.06%	Short Ratio	1.07	Perf Half Y	494.03%
Sales	0.70M	P/B	5.20	EPS next Y	-52.25%	ROA	-119.08%	Short Interest	0.07M	Perf YTD	-42.92%
Book/sh	9.56	P/C	4.99	EPS next 5Y	38.81%	ROE	-167.93%	52W High	240.00 -79.28%	Perf Year	55.95%
Cash/sh	9.97	P/FCF	-	EPS past 3/5Y	10.79% -17.92%	ROIC	-813.44%	52W Low	4.28 1063.04%	Perf 3Y	-74.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.41%	Volatility	20.41% 11.08%	Perf 5Y	-96.63%
Dividend TTM	-	EV/Sales	62.71	EPS Y/Y TTM	-17.93%	Oper. Margin	-7100.00%	ATR (14)	8.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.54	Sales Y/Y TTM	-90.18%	Profit Margin	-6869.30%	RSI (14)	29.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.54	EPS Q/Q	7.37%	SMA20	-32.83%	Beta	3.69	Target Price	205.75
Payout	-	Debt/Eq	0.25	Sales Q/Q	-100.00%	SMA50	-36.55%	Rel Volume	0.62	Prev Close	52.62
Employees	21	LT Debt/Eq	0.09	Earnings	Nov 10 AMC	SMA200	-2.23%	Avg Volume	66.82K	Price	49.72
IPO	Oct 09, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-4.63% -	Trades		Volume	41,489	Change	-5.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-23-25	Initiated	Oppenheimer	Outperform	$283
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform	$160
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$254

Feb-18-26 07:00AM	Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -8.18%
Feb-17-26 04:05PM	Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire) -12.14%
Feb-05-26 04:05PM	Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -10.58%
Feb-03-26 08:00AM	Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team (Business Wire) +7.05%
Jan-28-26 08:00AM	Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium (Business Wire)
07:24AM	Loading…
Jan-21-26 07:24AM	Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences (Benzinga) +10.44%
Jan-18-26 07:02PM	Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration (PR Newswire)
Jan-08-26 08:00AM	Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital (Business Wire) -5.62%
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-15-25 08:00AM	Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors (Business Wire)
Nov-10-25 04:05PM	Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (Business Wire) -8.97%
Oct-15-25 12:00PM	What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? (Zacks) -10.09%
Oct-08-25 08:00AM	Spruce Biosciences Announces $50.0 Million Private Placement Financing (Business Wire) -12.34%
09:44AM	Loading…
Oct-07-25 09:44AM	This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. (Barrons.com) +40.03%
Oct-06-25 05:04PM	Why Spruce Biosciences Just Skyrocketed Almost 1,400% (Investor's Business Daily) +1,378.46%
08:00AM	Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
Sep-15-25 07:00AM	Spruce Biosciences Resumes Trading on the Nasdaq Capital Market (Business Wire) -20.97%

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ways Douglas Kirk	Interim Chief Medical Officer	Dec 11 '25	Option Exercise	0.00	1,250	0	1,250	Jan 21 04:04 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 15 '25	Option Exercise	0.00	1,009	0	8,447	Dec 17 04:58 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 15 '25	Option Exercise	0.00	2,676	0	14,922	Dec 17 04:56 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 11 '25	Option Exercise	0.00	1,900	0	8,296	Dec 12 07:05 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 10 '25	Option Exercise	0.00	514	0	6,580	Dec 12 07:05 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 11 '25	Option Exercise	0.00	4,950	0	15,192	Dec 12 07:03 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 10 '25	Option Exercise	0.00	1,196	0	10,670	Dec 12 07:03 PM
Gharib Samir M.	PRESIDENT AND CFO	Oct 20 '25	Option Exercise	0.00	2,053	0	6,727	Oct 22 04:15 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Oct 20 '25	Option Exercise	0.00	4,784	0	11,013	Oct 22 04:15 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 08 08:55 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 08 08:55 PM

MPLT

MapLight Therapeutics Inc

IOBT

IO Biotech Inc

SPRB

Spruce Biosciences Inc

Upgrade your FINVIZ experience